Cross-border life-sciences collaborations—whether for drug discovery, medical devices, diagnostics or digital health platforms—are typically built on sophisticated IP-licensing structures. Yet when agreements cross multiple jurisdictions and legal cultures, even the best-drafted contracts can become unstable. Divergent national laws, discovery expectations and procedural habits frequently create friction that threatens scientific progress and commercial value.

Alternative dispute resolution (ADR)—that is, arbitration and mediation—offers a path through these hazards. Properly structured, ADR can deliver speed, neutrality, confidentiality and enforceability unmatched by litigation. Below are five recurring risks in cross-border life-sciences licensing—and how ADR can transform them into at least manageable variables.

Full article below: